Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactulose is a synthetic disaccharide composed of galactose and fructose that functions as both an osmotic laxative and a prebiotic. It is not absorbed in the upper gastrointestinal tract and reaches the colon intact, where it is fermented by commensal bacteria, particularly *Bifidobacterium* and *Lactobacillus* species. This fermentation produces short-chain fatty acids (such as lactic and acetic acids), which lower the colonic pH and exert an osmotic effect, drawing water into the lumen to soften stools and stimulate peristalsis. Beyond its primary use in chronic constipation, lactulose is a cornerstone therapy for hepatic encephalopathy; the acidified colonic environment converts ammonia (NH3) into non-absorbable ammonium ions (NH4+), effectively trapping it for excretion. Recent clinical research has explored its utility in modulating the gut-brain axis in Parkinson's disease, reducing uremic toxins in chronic kidney disease, and acting as an adjuvant therapy in inflammatory bowel disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lactulose.